Clinical study of CAR-T immune cell targeted therapy for recurrent/refractory CD19+ leukemia and lymphoma
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Anti-CD19-chimeric-antigen-receptor-T-cell-therapy-iCarTAB-Biomed (Primary) ; Cyclophosphamide
- Indications Leukaemia; Lymphoma
- Focus Pharmacodynamics; Therapeutic Use
- 27 Oct 2017 New trial record